SERUM INTERLEUKIN-10 LEVELS IN MULTIPLE SCLEROSIS PATIENTS TREATEDWITH IFN-Β 1A
Abstract:
Multiple sclerosis (MS) is an autoimmune chronic, manly demyelinating disease that affects
young adults. Interferon â (IFN-â) is the main immunomodulatory treatment in MS, used for more than
two decades but the exact mechanism of action is not totally understood. Evaluation of cytokine
production in IFN-â MS treated patients is important in clarifying both the pathological mechanisms of
MS and the IFN-â mode of action. Objective. To determine the serum IL-10 titre in MS patients treated
with IFN-â 1a im and to establish whether there is a correlation between IL-10 and demographic data,
neurological handicap, MS duration and treatment duration. Material and methods. A number of 17 MS
patients treated for at least 12 months with IFN-â 1a was included. For the quantitative detection of
human IL-10, the ELISA was used and the values were compared with those of 17 healthy controls.
Results. We found higher IL-10 titre in patients having a reduced EDSS, MS duration of maximum 5
years and in patients who had at least 3 years of IFN-â 1a treatment. None of these differences has a
significant difference. Conclusions. More research is needed to establish the role of IL-10 secretion in
MS patients treated with IFN-â.
full text article in Romanian (.RO) |
full text article in English (.EN) |